<DOC>
	<DOCNO>NCT01226823</DOCNO>
	<brief_summary>The study multicenter randomize double blind placebo control trial . The study conduct pregnant woman diagnosis intrahepatic cholestasis pregnancy ( ICP ) third level hospital ( also Academic Hospitals ) . Pregnant woman time ICP diagnosis randomize two group : Group 1 - receive placebo obstetrical monitoring delivery Group 2 - receive UDCA dose 20 mg/Kg/day obstetrical monitoring delivery . The hypothesis UDCA treatment superior placebo effective : reduce rate prematurity ; improve maternal biochemical parameter symptom .</brief_summary>
	<brief_title>Ursodeoxycholic Acid And Cholestasis Of Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Cholestasis , Intrahepatic</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Pregnant state ( week 20 gestation ) Total Serum BA elevation ( &gt; 10 micromol/l ) Transaminases elevation ( ALT &gt; 40 UI/L AST &gt; 37 UI/L ) Occurrence pruritus Informed consent sign Infectious disease ( HBV , HDV , HCV relate liver disease , EBV , CMV , HIV infection ) Dermatologic diseases Metabolic disease ( include alcohol abuse ) Other cause cholestasis ( i.e . PBC ; PSC ) Autoimmune liver disease Obstructive biliary disease Drug related pathology Known suspected hypersensibility drug pharmacological class study Serious clinical condition , accord judgment investigator , contraindicate participation study ( heart , kidney liver disease ) Use cholestyramine Patients able willing follow procedure protocol Patients sign informed consent Onset ICP 36th week pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cholestasis</keyword>
	<keyword>pregnancy</keyword>
	<keyword>ursodeoxycholic acid</keyword>
	<keyword>ICP</keyword>
</DOC>